Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)

This is an interventional treatment trial for Hodgkin's Disease focused on measuring Relapsed, Hodgkin's Disease, Methotrexate, 6-Thioguanine, 94-030 Read More

Inclusion Criteria:

• Patients with histologic proof of HD who are in relapse and have failed > or = to 2 prior chemotherapy regimens.
• Patients must have a life expectancy of at least 8 weeks.
• All patients must have ECOG performance level rating of < or = to 2.
• Patients or their parents (guardian) must sign an informed consent indicating that they are aware of the investigational nature of the study.
• Patients must have recovered from the toxic effects of prior therapy before entering this study or at least 2 weeks should have elapsed since the end of last course of CT.
• Patients must have adequate liver function (bilirubin < or = to 2.0 mg/dl, SGOT less than 1.5 times normal (unless it is due to disease), adequate renal function (creatinine < or = to 1.5 mg/dl, creatinine clearance > or = to 60 ml/min/1.73 m2).
• Patients should have a granulocyte count > or = to 500/gL and a platelet count > or = to 100,000/uL (unless due to disease involvement of the bone marrow).
• Male and female patients of child-bearing age should use effective methods of contraception, if sexually active.

Exclusion Criteria:

• Patients with active infections or significant medical conditions other than their malignancy shall be excluded.
• Patients with HD who had prior MTX or 6-TG should be excluded.